DAIC

FEBRUARY 2, 2024

Photo: Edwards Lifesciences milla1cf Fri, 02/02/2024 - 09:33 February 2, 2024 — Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).

Tricuspid 100

Tricuspid Quality of Life Bicuspid/Mitral Innovation 100

DAIC

APRIL 30, 2024

milla1cf Tue, 04/30/2024 - 13:03 April 30, 2024 — The expanding use of transcatheter technologies has changed the landscape in the treatment of valvular disease in adult cardiac patients, with valve surgery rapidly shifting to more complex interventions frequently involving other concomitant procedures. and 4.1%, respectively.

TAVR 111

TAVR Aortic valve Tricuspid Coronary Artery Bypass Graft 111

DAIC

DECEMBER 22, 2023

Tricuspid regurgitation (TR) is a common and serious disease for which open heart surgery and symptomatic pharmacologic treatment are the current standard treatment options. Owing to high mortality risk, access to open heart surgery is severely restricted and is not considered an option for most patients with TR.

Tricuspid 59

Tricuspid Pacemaker Heart Valves Open-Heart Surgery 59

Circulation: Cardiovascular Interventions

NOVEMBER 9, 2023

Background:There are limited data about changes in cardiac function (cardiac reverse remodeling) and heart failure indices after transcatheter tricuspid valve-in-valve replacement (TT-VIVR).

Congenital Heart Disease 40

Congenital Heart Disease Tricuspid Heart Failure Congenital 40

DAIC

JUNE 27, 2024

Attendees can join with their peers and participate in sessions on structural heart disease, congenital heart disease, guidelines and trials, AI/Machine learning, technical aspects of cardiac CT, coronary artery disease, vascular heart disease, debates and games and early career topics. 5:00 p.m.,

Congenital Heart Disease 105

Congenital Heart Disease Coronary Artery Disease Congenital Heart Disease 105

Dr. Smith's ECG Blog

JANUARY 1, 2024

His medical history includes hypertension, a decade-long battle with diabetes, ischemic heart disease, a coronary bypass graft surgery ten years ago, a diagnosis of congestive heart failure for the last five years, and a prior ICD implantation five years ago.

Tachycardia 112

Tachycardia Blog Ischemia Heart Failure 112

Dr. Smith's ECG Blog

JUNE 2, 2023

There is mild-moderate tricuspid valve regurgitation. 756-764 Google Scholar == MY Comment , by K EN G RAUER, MD ( 6/3 /2023 ): == Today's case is gratifying — in that it illustrates an uncommon phenomenon that Dr. Meyers picked up with potential life-saving implications. The basal anterior wall and basal septum are hypokinetic.

Tachycardia 96

Tachycardia Cardiomyopathy Electrocardiogram Article 96